<DOC>
	<DOC>NCT01769066</DOC>
	<brief_summary>The aim of this study is to explore the Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum compare with Pemetrexed/Platinum for Advanced NSCLC.</brief_summary>
	<brief_title>Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC</brief_title>
	<detailed_description>Patients will be randomized to 2 groups</detailed_description>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1. 18~70 years 2. Patients who were diagnosed by the histologic, cytologic diagnosis of IIIbIV nonsmall cell lung cancer 3. Presence of at least one index lesion measurable by CT scan or MRI 4. Ecog01 5. Expected life time longer than 12 weeks 6. Normal laboratory values: leucocyte ≥ 4×109/L neutrophil ≥ 1.5×109/L platelet ≥ 100×109/L Hemoglobin ≥ 10g/L ALT and AST ≤ 2.5×ULN (≤ 5×ULN if liver metastasis) 7. Signed written informed consent Patients have used drugs according to protocol Patients were allergic to pemetrexed or cisplatin Patients received radiotherapy or other biological treatment 4 weeks before the trial Uncontrolled hydrothorax or hydropericardium neuropathy toxicity ≥ CTC 3 Severe symptomatic heart disease Active upper gastrointestinal ulcer or digestive disfunction Severe infection or metabolic disfunction Patients with other malignant tumor Uncontrolled brain metastases Patients have accepted other clinical trials Female patients during their pregnant and lactation period, or patients without contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>